Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine

Phase 4

Not yet recruiting

Conditions: Psychosis

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 20

Registration Number: NCT06546475

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients

Not Applicable

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Syrup Prospan
Drug: N-Acetylcysteine

First Posted Date: 2024-04-22

Last Posted Date: 2024-08-20

Lead Sponsor: National University of Malaysia

Target Recruit Count: 100

Registration Number: NCT06377410

Locations: 🇲🇾
National University of Malaysia, Faculty of Medicine, Cheras, Kuala Lumpur, Malaysia
🇲🇾
National University of Malaysia, Cheras, Kuala Lumpur, Malaysia

Tolerability of Enteral NAC in Infants

Phase 1

Not yet recruiting

Conditions: Biliary Atresia

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2024-02-15

Last Posted Date: 2024-04-15

Lead Sponsor: Sanjiv Harpavat

Target Recruit Count: 12

Registration Number: NCT06260566

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Both N-acetylcysteine and Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Phase 3

Recruiting

Conditions: Hepatic and Post Hepatic Jaundice

Interventions: Drug: N-acetylcysteine
Drug: Pentoxifylline

First Posted Date: 2024-02-01

Last Posted Date: 2024-11-22

Lead Sponsor: Tanta University

Target Recruit Count: 66

Registration Number: NCT06236165

Locations: 🇪🇬
Faculty of Pharmacy, Tanta University, Tanta, Egypt

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Phase 3

Recruiting

Conditions: Dry Age-related Macular Degeneration

Interventions: Drug: Aspirin 81Mg Ec Tab
Drug: Clopidogrel
Drug: N-acetylcysteine

First Posted Date: 2023-12-11

Last Posted Date: 2023-12-15

Lead Sponsor: Navamindradhiraj University

Target Recruit Count: 174

Registration Number: NCT06165068

Locations: 🇹🇭
Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University, Bangkok, Dusit, Thailand

NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: N-acetyl-L-cysteine

First Posted Date: 2023-09-05

Last Posted Date: 2024-11-07

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 30

Registration Number: NCT06024031

Locations: 🇨🇳
Yuan Kong, Beijing, Beijing, China

Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity

Not Applicable

Active, not recruiting

Conditions: Drug Toxicity

Interventions: Drug: N-Acetylcysteine
Drug: Chemotherapy

First Posted Date: 2023-08-31

Last Posted Date: 2023-08-31

Lead Sponsor: Foundation University Islamabad

Target Recruit Count: 70

Registration Number: NCT06019520

Locations: 🇵🇰
Medical Oncology department, Fauji Foundation Hospital, Rawalpindi, Punjab, Pakistan

NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM

Phase 1

Withdrawn

Conditions: Atherosclerosis of Artery
Peripheral Artery Disease
Diabetes Mellitus
Inflammation
Oxidative Stress

Interventions: Drug: Placebo
Drug: N-acetylcysteine

First Posted Date: 2023-06-18

Last Posted Date: 2023-06-18

Lead Sponsor: University of Missouri-Columbia

Registration Number: NCT05908513

Locations: 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China

Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction

Phase 4

Completed

Conditions: Nicotine Dependence
Nicotine Addiction

Interventions: Drug: n-acetylcysteine
Behavioral: Motivational Enhancement Therapy

First Posted Date: 2023-06-15

Last Posted Date: 2024-10-08

Lead Sponsor: Indonesia University

Target Recruit Count: 90

Registration Number: NCT05903014

Locations: 🇮🇩
Faculty of Medicine, Universitas Indonesia, Jakarta, DKI Jakarta, Indonesia

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Not Applicable

Completed

Conditions: Upper Respiratory Tract Infections

Interventions: Drug: 0.9% NaCl physiological saline Nasal-spraying
Combination Product: LiveSpo Navax®
Drug: Augmentin 500Mg Tablet
Drug: Acetylcysteine
Drug: Xylometazoline Nasal
Drug: Cefotaxime
Drug: Ciprofloxacin

First Posted Date: 2023-04-07

Last Posted Date: 2024-08-22

Lead Sponsor: Anabio R&D

Target Recruit Count: 175

Registration Number: NCT05804123

Locations: 🇻🇳
Thai Binh University of Medicine and Pharmacy, Thai Binh Medical University Hospital and Thai Binh Children's Hospital, Thai Binh, Vietnam

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy